Effects of the Combination of Neoadjuvant Immunotherapy with Chemotherapy versus Placebo with Chemotherapy on Pathologic Complete Response in Early Triple-Negative Breast Cancer: A Systematic Review
Asian Journal of Research in Surgery, Volume 6, Issue 2,
Introduction: One of the most aggressive forms of breast cancer is triple-negative breast cancer (TNBC). TNBC has a poor prognosis and limited therapeutic options. Therefore, therapeutic intervention is strongly suggested when treatment with the intention of cure is still possible. Chemotherapy and immune checkpoint inhibitors have already been utilized to raise the pathologic complete response (pCR) rates in early-stage TNBC patients.
Objectives: The study aims to assess the efficacy of neoadjuvant immunotherapy in combination with chemotherapy, in the early-stage TNBC, with the primary endpoint of pCR (ypT0/is ypN0).
Methods: The medical term “Immunotherapy”, “Pembrolizumab”, “Atezolizumab”, “Durvalumab”, “Neoadjuvant treatment”, and “Triple-negative breast cancer”, were used in Pubmed and Google Scholar to discover studies of the efficacy of immunotherapy combined with chemotherapy in early-stage TNBC by following the PICO framework up to January 2023. All phase 1, 2, and 3 clinical studies demonstrating safety and efficacy data were included. Two independent reviewers excluded the non-RCTs and other clinical studies irrelevant to the study question. Five remaining studies were reviewed and screened for the inclusion criteria, based on the relevance to the study subject and clinical outcomes.
Results: Based on five studies included in this review, a combination of immunotherapy (pembrolizumab, atezolizumab, or durvalumab) with chemotherapy has shown superior effects of increasing pCR rates, compared to the chemotherapy alone, regardless of PD-L1 status, in early-stage TNBC. Adverse events were not more frequently reported with the immunotherapy compared to placebo.
Conclusions: A combination of neoadjuvant immunotherapy with chemotherapy has revealed superior effects of increasing pCR rates, compared to the chemotherapy alone in early-stage TNBC, irrespective of PD-L1 status, with an acceptable safety profile. However, further studies are needed to explore this issue.
- neoadjuvant treatment
- triple-negative breast cancer
How to Cite
Globocan. Global Cancer Statistics. Who “Estimated number of deaths in 2020, World, females, all ages. 2020;996: 2020.
Y. Cui et al. Antibody drug conjugates of near-infrared photoimmunotherapy (NIR-PIT) in breast cancers. Technol. Cancer Res. Treat. 2023;22. DOI: 10.1177/15330338221145992.
Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for triple-negative breast cancer : combination strategies to improve outcome; 2023.
Schmid P, et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 2020; 382(9):810–821.
Saji S, et al. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab -paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). 2022;52(June):1124–1133.
Liu Y, Zheng L, Cai X, Zhang X. Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. 2020;2(2).
Huang M, et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer : A meta-analysis. 2020;October 2018: 5427–5434. DOI: 10.1158/0008-5472.CAN-20-1792
Brown LC, Loi S. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer : 2021 update. The Breast. 2022;62:S29–S33. DOI: 10.1016/j.breast.2021.12.018.
Deng H, et al. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe ‑ negative breast cancer : exploratory analysis of real ‑ world, multicenter data. BMC Cancer. 20231–9.
Mittendorf EA, et al. Articles neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early- stage triple-negative breast cancer (IMpassion031 ): a randomised , double-blind. 2020;2(20):1–11.DOI: 10.1016/S0140-6736(20)31953-X.
Nanda R, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684. DOI: 10.1001/jamaoncol.2019.6650.
Loibl S, et al. Original article A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study. 2019;May:1279–1288. DOI: 10.1093/annonc/mdz158.
Ashar M, Aiman W, Shah SS, Hussain M, Kashyap R. Critical reviews in oncology / hematology efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer : A systematic review of clinical trials. Crit. Rev. Oncol. / Hematol. 2021;157(December 2020): 103197. DOI: 10.1016/j.critrevonc.2020.103197
Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Critical reviews in oncology / hematology immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer : A systematic review and meta-analysis of randomized clinical trials. Crit. Rev. Oncol. / Hematol. 2021;159(January):103223.
Emens, Leisha A. Immunotherapy in Triple-Negative Breast Cancer. The Cancer Journal. 2021;27(1):59-66.
Xin Y, et al. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer : A systematic review and meta-analysis. BMC Cancer. 2021;1–10. DOI: 10.1186/s12885-021-08997-w
Abstract View: 0 times
PDF Download: 0 times